Thank you

This live web event has ended. Thank you for attending.

Description

New Perspectives on the Full Spectrum
of HER2 Expression in Breast Cancer

Why should you register now for this webinar?

• While identifying HER2-positive breast cancers has been the objective in clinical practice for the past 20 years, active research is exploring clinical relevance of HER2 across the full spectrum of expression, including low levels 
• As the field evolves, it is becoming increasingly relevant to evaluate and differentiate each level of HER2 expression, as it may have implications for
  patient care

Brought to you by CAP TODAY
Moderated by Bob McGonnagle, Publisher, CAP TODAY
Presenter: Gary Tozbikian, MD
You will have the opportunity to ask questions of our distinguished presenter

CAP TODAY does not endorse any of the products or services named within.
This program is not CME accredited and no CME credit will be provided.
This webinar is sponsored by Daiichi Sankyo, Inc. and AstraZeneca.
The speaker is receiving compensation for this presentation.Daiichi Sankyo and AstraZeneca are committed to furthering the research and development of potential therapies for women with metastatic breast cancer across the spectrum of HER2 expression

©2022 Daiichi Sankyo, Inc. and AstraZeneca. All rights reserved. PP-US-8201a-1293. 05/22